TFGβ is a key regulator of EMT and it was shown that TGFβ treatment of human HCC cells PLC/PRF/5 resulted in upregulation of multiple RTKS, such as IGF1R, EGFR, PDGFBR, and FGFR1, resulting in sorafenib resistance [88]. This evidence concerns the gene EGFR and hepatocellular carcinoma.